{"id":9830,"date":"2016-10-05T16:41:56","date_gmt":"2016-10-05T19:41:56","guid":{"rendered":"http:\/\/www.amchamchile.cl\/?p=148778"},"modified":"2016-11-02T11:52:48","modified_gmt":"2016-11-02T14:52:48","slug":"miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo","status":"publish","type":"news","link":"https:\/\/amchamchile.cl\/en\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/","title":{"rendered":"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:]"},"content":{"rendered":"

[:es]En base a biolog\u00eda molecular se busca democratizar el acceso al diagn\u00f3stico de esta enfermedad en etapas tempranas. Una vez que salga al mercado supondr\u00e1 un salto cu\u00e1ntico en la medicina.<\/em>\u00a0<\/em><\/p>\n

Por Catalina Jofr\u00e9<\/strong><\/p>\n

Alejandro Tocigl (Chile), Jorge Soto (M\u00e9xico) y Foteini Christodoulou (Grecia) se conocieron hace tres a\u00f1os cursando un programa de Singularity University, instituci\u00f3n acad\u00e9mica y aceleradora de negocios ubicada en Silicon Valley, el cual tiene por objetivo promover la innovaci\u00f3n con impacto social.<\/p>\n

Una vez all\u00ed, con intereses en com\u00fan y un proyecto por presentar para graduarse, los tres emprendedores comenzaron a idear lo que hoy es Miroculus, una tecnolog\u00eda y un dispositivo, que juntos son capaces de\u00a0 diagnosticar de manera precoz el c\u00e1ncer, a trav\u00e9s del an\u00e1lisis de sangre donde se detectan mol\u00e9culas de microRNA, aquellas que se relacionan a ciertas a enfermedades y act\u00faan como biomarcadores.<\/p>\n

En un principio, los motivaba el estar insertos en un ambiente donde todo parec\u00eda propicio para las nuevas ideas, pero deb\u00edan pasar una prueba un poco m\u00e1s dif\u00edcil, el elegir entre esta nueva apuesta y las carreras profesionales que hab\u00edan construido con antelaci\u00f3n.<\/p>\n

Para probar si exist\u00eda inter\u00e9s en apostar por Miroculus, acordaron volver a sus respectivos pa\u00edses y trabajos y evaluar, en un plazo de un mes, si exist\u00eda inter\u00e9s. \u201cNunca nos dimos el mes sino que a los tres d\u00edas ya est\u00e1bamos pensando en c\u00f3mo dar vida al proyecto y c\u00f3mo ser un aporte para la salud\u201d, reconoce Tocigl.<\/p>\n

El camino a ser una empresa<\/strong><\/p>\n

Lo que vino despu\u00e9s fue el camino hacia convertirse en una firma, reunirse y volver a trabajar juntos.<\/p>\n

Para levantar sus primeros fondos postularon a tres concursos de emprendimiento en sus respectivos pa\u00edses de origen. En Chile resultaron ganadores de Desaf\u00edo Clave, en M\u00e9xico de Gifted Citizens y en Grecia de SFEE Innovation Project. Con esos recursos instalaron un laboratorio en el Instituto de Biolog\u00eda Molecular de Europa, en Heidelberg (Alemania) y realizaron su primera prueba de concepto a fines de 2014.<\/p>\n

Con este primer paso logrado, se dedicaron tiempo completo a darle vida a Miroculus. La idea que ten\u00edan en mente era lograr un desarrollo de punta diferente a las tecnolog\u00edas costosas que se conocen en la actualidad.<\/p>\n

Para avanzar, en paralelo, Tocigl se reuni\u00f3 con Soto en M\u00e9xico para trabajar en el hardware<\/em> y software<\/em>, mientras Christodoulou, radicada en Alemania, avanzaba en el \u00e1mbito de la bioqu\u00edmica.<\/p>\n

\u201cConstantemente ve\u00edamos que los \u00faltimos desarrollos en medicina estaban disponibles s\u00f3lo para el 1% de la poblaci\u00f3n que puede pagarlos. (\u2026) Eso nos motiv\u00f3, pero tambi\u00e9n pensamos en los recursos disponibles en econom\u00edas emergentes\u201d, afirma Tocigl.<\/p>\n

Rumbo a Estados Unidos<\/strong><\/p>\n

Tras levantar capital para desarrollar el prototipo, a principios de 2015 se trasladaron a la Universidad de California, en San Francisco, Estados Unidos. Una vez all\u00ed realizaron una segunda ronda de inversi\u00f3n, en la que levantaron US$ 5 millones, aportados por fondos de capital de riesgo \u00a0y family offices<\/em> de Latinoam\u00e9rica, EE.UU. y China. Estos recursos les permitieron iniciar los estudios cl\u00ednicos y aumentar el equipo de trabajo a las 13 personas que hoy conforman la empresa.<\/p>\n

Los estudios cl\u00ednicos se realizaron en colaboraci\u00f3n con el National Institutes of Health (NIH), la Universidad Cat\u00f3lica de Chile y con dos hospitales m\u00e1s en Europa y en M\u00e9xico, enfoc\u00e1ndose en el c\u00e1ncer de est\u00f3mago, uno de los m\u00e1s prevalentes dentro de econom\u00edas en v\u00edas de desarrollo.<\/p>\n

\u201cConsiderando a 650 pacientes con c\u00e1ncer de est\u00f3mago comenzamos un estudio en pacientes con esta enfermedad y pacientes sanos, basados en una combinaci\u00f3n de estas mol\u00e9culas encontradas en la sangre\u201d, relata.<\/p>\n

El proceso, que tom\u00f3 alrededor de un a\u00f1o, dio paso a su desaf\u00edo actual que consiste en adaptar esta combinaci\u00f3n de mol\u00e9culas a sus plataformas, esto porque que el algoritmo matem\u00e1tico que permite diferenciar entre las dos condiciones posibles fue probado inicialmente en los sistemas tradicionales.<\/p>\n

Proyecciones<\/strong><\/p>\n

Los fundadores de Miroculus, que hoy es parte de la red de emprendedores de endeavour, destacan el impacto que una tecnolog\u00eda como la que ellos desarrollan podr\u00eda tener en pa\u00edses donde este tipo de c\u00e1ncer es un problema. Pues, independiente de que busquen hacer una soluci\u00f3n m\u00e1s asequible, la mayor ganancia que pueden obtener no se mide en dinero, sino en la posibilidad de descongestionar los sistemas de salud y ganar tiempo contra el c\u00e1ncer, explica Tocigl.<\/p>\n

\"untitled\"<\/p>\n

Con esta tecnolog\u00eda se podr\u00eda llegar a muchas m\u00e1s personas y acortar las listas de espera para recibir una endoscopia, las que, en algunos lugares en Chile, afirma, pueden llegar a un extremo de hasta cuatro a\u00f1os. \u201cHay gente que se ha muerto en listas de espera para una endoscopia. Lo que nosotros proponemos es, a trav\u00e9s de una muestra de sangre, priorizar a quienes realizar una endoscopia\u201d, expresa el emprendedor chileno.<\/p>\n

Para generar un mayor impacto, la tecnolog\u00eda est\u00e1 pensada para llegar, en un principio, a econom\u00edas emergentes como M\u00e9xico, Colombia, pa\u00edses asi\u00e1ticos y Chile, donde el c\u00e1ncer de est\u00f3mago encabeza la lista de los m\u00e1s mortales. Para lograrlo, planean realizar un tercer levantamiento de capital en 2017, a fin de llegar al mercado mexicano en 2018.<\/p>\n

A la fecha, ya cuentan con tres patentes otorgadas en EE.UU. y 35 en curso en diferentes pa\u00edses.<\/p>\n

La tecnolog\u00eda de Miroculus es de gran impacto social y con grandes proyecciones para llegar a mercados en todo el mundo. Pero su aporte no se agota ah\u00ed, pues ya est\u00e1n buscando detectar otras enfermedades, principalmente de car\u00e1cter infeccioso, utilizando otros biomarcadores bajo el mismo sistema, lo que sin duda, seguir\u00e1 dando que hablar en los pr\u00f3ximos a\u00f1os.<\/p>\n

\u00bfC\u00f3mo funciona Miroculus?<\/strong><\/p>\n

El sistema opera con una muestra de sangre de un paciente, la que luego de separarse del plasma, se inserta y analiza en un dispositivo, que determina la presencia o ausencia y en qu\u00e9 cantidad, est\u00e1 la combinaci\u00f3n de mol\u00e9culas llamadas MicroARN, relacionadas con el c\u00e1ncer de est\u00f3mago. En un lapso de dos horas, el sistema arroja un resultado que se aloja en la nube y se env\u00eda el doctor en formato de reporte. Esto le permitir\u00e1 decidir si es un paciente prioritario o no.[:en]Based on molecular biology, Miroculus is seeking to democratize access to the diagnosis of early-stage cancer. Once it reaches national markets, its model will be a quantum leap for medicine.<\/em>\u00a0<\/em><\/p>\n

By Catalina Jofr\u00e9<\/strong><\/p>\n

Alejandro Tocigl (from Chile), Jorge Soto (from Mexico) and Foteini Christodoulou (from Greece) met three years ago while studying at Singularity University, an academic and business incubator institution in Silicon Valley, on a course that aimed to promote innovation with a social impact.<\/p>\n

With the common interest of the need to devise a project to graduate from this course, the three students began to develop what has today become Miroculus; a company that develops technology and instruments that, when used in combination, are capable of achieving the early diagnosis of cancer. This is done by means of blood analysis to detect microRNA molecules, which are related to, and act as biomarkers of, certain diseases.<\/p>\n

Initially, the motivation of the three entrepreneurs stemmed from their exposure to an environment in which everything seemed to be conducive to new ideas. However, they were soon forced to make a difficult decision: choosing between their new endeavor or the professional careers they had built up beforehand.<\/p>\n

To see whether it was worth pursuing Miroculus, they all agreed to return to their respective countries and jobs and to evaluate, over the course of one month, whether there was wider interest or not in this particular field. \u201cWe didn\u2019t need a whole month, because just three days in and we were already thinking about how to consolidate the project and in what way we could contribute to healthcare\u201d, recalls Tocigl.<\/p>\n

The path to becoming a company<\/strong><\/p>\n

What followed was their journey to founding a formal company, including all three of them working together again.<\/p>\n

To raise their initial funds, they applied for three entrepreneurial grants in their respective countries. In Chile they won Desaf\u00edo Clave (Key Challenge), in Mexico they came first in Gifted Citizens, and in Greece they were awarded the SFEE Innovation Project. With the financial resources secured, they proceeded to open a laboratory in the European Molecular Biology Laboratory in Heidelberg, Germany, where they conducted their first concept testing at the end of 2014.<\/p>\n

With the first phase complete, they set about the process of fully consolidating Miroculus and committing to their goal of developing alternatives to technologies that are currently highly expensive.<\/p>\n

To make progress towards this end, Tocigl met with Soto in Mexico to work on hardware and software issues, while Christodoulou, located in Germany, continued to develop the biochemistry side.<\/p>\n

\u201cWhat we constantly saw was that the latest developments in medicine were only available for the 1% of the population who could afford to pay for them. (…) This motivated us, and we were all fully aware of the resources available in emerging economies\u201d, explains Tocigl.<\/p>\n

On to the United States<\/strong><\/p>\n

Having raised the capital to develop the prototype, the three entrepreneurs moved to the University of California, in San Francisco, in early 2015. Here, they began a second round of raising capital, securing US$5 million from risk capital funds and family office investments from Latin America, the US and China. These resources enabled them to begin clinical studies and to expand their work team to the 13 people that make up the company today.<\/p>\n

The clinical studies were conducted in collaboration with the US National Institutes of Health, the Universidad Cat\u00f3lica de Chile and two further hospitals in Europe and Mexico. Their research focused on stomach cancer, one of the most prevalent types of cancers in developing nations.<\/p>\n

Tocigl notes that, \u201cBy evaluating 650 patients with stomach cancer, we began a study on individuals who either had the disease or who were healthy, based on a combination of molecules found in their blood\u201d.<\/p>\n

This process, which took approximately one year to complete, gave rise to Miroculus\u2019 current challenge, which is to adapt this combination of molecules to their particular platform. This is because the mathematical algorithm that enables the detection of differences between the two possible conditions was initially found only in traditional systems.<\/p>\n

Projections<\/strong><\/p>\n

The founders of Miroculus, which today forms part of Endeavor\u2019s network of entrepreneurs, are keen to highlight the impact that a technology such as the one they are developing could have on countries in which stomach cancer is a problem. Regardless of the fact that they are seeking a more affordable solution, Tocigl points out that the greatest benefit will not be measured financially, but rather in terms of helping to decongest health systems and biding time for the fight against cancer.<\/p>\n

\"untitled\"<\/p>\n

This technology can reach far greater numbers of people and shorten waiting times for endoscopies, which in certain places in Chile can be up to four years. \u201cThere are many people who have died waiting for an endoscopy. What we propose is, by means of a blood sample, to prioritize those on the waiting list for this type of procedure based on the severity of their condition\u201d, explains the Chilean entrepreneur.<\/p>\n

To generate a greater impact, the idea is for this technology to initially reach emerging markets such as Mexico, Colombia, a number of Asian countries, and Chile, where stomach cancer tops the list of the most mortal types of the disease. To achieve this, Miroculus plans to stage a third round of raising capital in 2017, in order to reach the Mexican market in 2018.<\/p>\n

To date, the company has had three patents granted in the US and has 35 currently under submission in a number of different countries.<\/p>\n

Miroculus\u2019 technology is having a large social impact and is projected to reach markets right around the world. However, its influence does not end there because the company is already seeking to identify other diseases, primarily those of an infectious nature, using other biomarkers under the same system. Undoubtedly, these efforts will continue to attract attention over the coming years.<\/p>\n

How does Miroculus work?<\/strong><\/p>\n

The system operates with a patient’s blood sample. Following the separation of the plasma from the blood, the sample is inserted into a device for analysis purposes in order to determine the presence or absence, and quantity, of molecules called MicroRNAs, which are related to stomach cancer. Within a period of two hours, the system produces a result which is stored in a computing cloud and sent to the corresponding doctor in a report format. This enables the doctor to decide whether the patient is a priority or not.[:]<\/p>\n","protected":false},"excerpt":{"rendered":"

[:es]En base a biolog\u00eda molecular se busca democratizar el acceso al diagn\u00f3stico de esta enfermedad en etapas tempranas. Una vez que salga al mercado supondr\u00e1 un salto cu\u00e1ntico en la medicina.\u00a0 Por Catalina Jofr\u00e9 Alejandro Tocigl (Chile), Jorge Soto (M\u00e9xico) y Foteini Christodoulou (Grecia) se conocieron hace tres a\u00f1os cursando un programa de Singularity University, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"template":"","news_tax":[],"user_type":[],"class_list":["post-9830","news","type-news","status-publish","hentry"],"acf":[],"yoast_head":"\n[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:] - AmCham Chile<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:] - AmCham Chile\" \/>\n<meta property=\"og:description\" content=\"[:es]En base a biolog\u00eda molecular se busca democratizar el acceso al diagn\u00f3stico de esta enfermedad en etapas tempranas. Una vez que salga al mercado supondr\u00e1 un salto cu\u00e1ntico en la medicina.\u00a0 Por Catalina Jofr\u00e9 Alejandro Tocigl (Chile), Jorge Soto (M\u00e9xico) y Foteini Christodoulou (Grecia) se conocieron hace tres a\u00f1os cursando un programa de Singularity University, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/\" \/>\n<meta property=\"og:site_name\" content=\"AmCham Chile\" \/>\n<meta property=\"article:modified_time\" content=\"2016-11-02T14:52:48+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/\",\"url\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/\",\"name\":\"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:] - AmCham Chile\",\"isPartOf\":{\"@id\":\"https:\/\/amchamchile.cl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg\",\"datePublished\":\"2016-10-05T19:41:56+00:00\",\"dateModified\":\"2016-11-02T14:52:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#primaryimage\",\"url\":\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg\",\"contentUrl\":\"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/amchamchile.cl\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:]\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/amchamchile.cl\/#website\",\"url\":\"https:\/\/amchamchile.cl\/\",\"name\":\"AmCham Chile\",\"description\":\"C\u00e1mara Chilena Norteamericana de Comercio\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/amchamchile.cl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:] - AmCham Chile","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/","og_locale":"en_US","og_type":"article","og_title":"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:] - AmCham Chile","og_description":"[:es]En base a biolog\u00eda molecular se busca democratizar el acceso al diagn\u00f3stico de esta enfermedad en etapas tempranas. Una vez que salga al mercado supondr\u00e1 un salto cu\u00e1ntico en la medicina.\u00a0 Por Catalina Jofr\u00e9 Alejandro Tocigl (Chile), Jorge Soto (M\u00e9xico) y Foteini Christodoulou (Grecia) se conocieron hace tres a\u00f1os cursando un programa de Singularity University, […]","og_url":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/","og_site_name":"AmCham Chile","article_modified_time":"2016-11-02T14:52:48+00:00","og_image":[{"url":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/","url":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/","name":"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:] - AmCham Chile","isPartOf":{"@id":"https:\/\/amchamchile.cl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#primaryimage"},"image":{"@id":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#primaryimage"},"thumbnailUrl":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg","datePublished":"2016-10-05T19:41:56+00:00","dateModified":"2016-11-02T14:52:48+00:00","breadcrumb":{"@id":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#primaryimage","url":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg","contentUrl":"http:\/\/amchamchile.cl\/wp-content\/uploads\/2016\/10\/Miroculus_2-1024x679.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/amchamchile.cl\/noticia\/miroculus-y-la-cruzada-contra-el-cancer-en-el-mundo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/amchamchile.cl\/en\/"},{"@type":"ListItem","position":2,"name":"[:es]Miroculus y la cruzada contra el c\u00e1ncer en el mundo[:en]Miroculus and the global fight against cancer [:]"}]},{"@type":"WebSite","@id":"https:\/\/amchamchile.cl\/#website","url":"https:\/\/amchamchile.cl\/","name":"AmCham Chile","description":"C\u00e1mara Chilena Norteamericana de Comercio","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/amchamchile.cl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news\/9830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news\/9830\/revisions"}],"wp:attachment":[{"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/media?parent=9830"}],"wp:term":[{"taxonomy":"news_tax","embeddable":true,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/news_tax?post=9830"},{"taxonomy":"user_type","embeddable":true,"href":"https:\/\/amchamchile.cl\/en\/wp-json\/wp\/v2\/user_type?post=9830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}